Immunogenicity of Adalimumab in Patients with Non-Infectious- Uveitis: Systematic Review and Meta-Analysis

Diana Isabel Pachón-Suárez; Laura Zárate-Pinzón; Carlos Cifuentes-González; William Rojas-Carabali; Germán Mejía-Salgado; Juan Sebastián Pineda; Luisa Fernanda Peña-Pulgar; Alejandra de-la-Torre

doi:10.1080/09273948.2023.2256850

Immunogenicity of Adalimumab in Patients with Non-Infectious- Uveitis: Systematic Review and Meta-Analysis

Diana Isabel Pachón-Suárez
, Laura Zárate-Pinzón
, Carlos Cifuentes-González
, William Rojas-Carabali
, Germán Mejía-Salgado
, Juan Sebastián Pineda
, Luisa Fernanda Peña-Pulgar
, Alejandra de-la-Torre

Research output: Contribution to Journal › Research Article › peer-review

7 Scopus citations

Abstract

Objective: To review the prevalence, incidence, and risk factors for developing anti-drug antibodies (AAA) in patients with non-infectious uveitis (NIU) treated with Adalimumab (ADA). Methods: A systematic literature search was performed on PubMed, EMBASE, Virtual Health Library, Cochrane, and medRxiv. Meta-analysis was performed using random effects. Results: Nine out of 2,373 studies were included. The prevalence of AAA in NIU patients treated with ADA was 9% (95% CI: 2% to 37%, I² = 95% with a P<0.01), it was significantly higher in real-life scenarios (observational studies) than in clinical trials. The pooled incidence at 12 months was 27% (CI 95% 16%-42% I² = 0%). Several factors have been associated with AAA generation in NIU patients, including the non-use of concomitant immunosuppressants, presence of autoimmune systemic disease, female gender, etc. Conclusion: This study showed that AAA prevalence is higher in real-life scenarios compared to clinical trials. Further research is needed to elucidate the factors that trigger AAA generation in NIU patients.

Translated title of the contribution	Inmunogenicidad de adalimumab en pacientes con uveítis no infecciosa: Revisión sistemática y metaanálisis
Original language	English (US)
Journal	Ocular Immunology and Inflammation
DOIs	https://doi.org/10.1080/09273948.2023.2256850
State	Published - Oct 5 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Immunology and Allergy
Ophthalmology

Access to Document

10.1080/09273948.2023.2256850

Cite this

@article{fb509d53bfa74fd19d4c265807c103ec,

title = "Immunogenicity of Adalimumab in Patients with Non-Infectious- Uveitis: Systematic Review and Meta-Analysis",

abstract = "Objective: To review the prevalence, incidence, and risk factors for developing anti-drug antibodies (AAA) in patients with non-infectious uveitis (NIU) treated with Adalimumab (ADA). Methods: A systematic literature search was performed on PubMed, EMBASE, Virtual Health Library, Cochrane, and medRxiv. Meta-analysis was performed using random effects. Results: Nine out of 2,373 studies were included. The prevalence of AAA in NIU patients treated with ADA was 9\% (95\% CI: 2\% to 37\%, I2 = 95\% with a P<0.01), it was significantly higher in real-life scenarios (observational studies) than in clinical trials. The pooled incidence at 12 months was 27\% (CI 95\% 16\%-42\% I2 = 0\%). Several factors have been associated with AAA generation in NIU patients, including the non-use of concomitant immunosuppressants, presence of autoimmune systemic disease, female gender, etc. Conclusion: This study showed that AAA prevalence is higher in real-life scenarios compared to clinical trials. Further research is needed to elucidate the factors that trigger AAA generation in NIU patients.",

author = "Pach{\'o}n-Su{\'a}rez, \{Diana Isabel\} and Laura Z{\'a}rate-Pinz{\'o}n and Carlos Cifuentes-Gonz{\'a}lez and William Rojas-Carabali and Germ{\'a}n Mej{\'i}a-Salgado and Pineda, \{Juan Sebasti{\'a}n\} and Pe{\~n}a-Pulgar, \{Luisa Fernanda\} and Alejandra de-la-Torre",

note = "Publisher Copyright: {\textcopyright} 2023 Taylor \& Francis Group, LLC.",

year = "2023",

month = oct,

day = "5",

doi = "10.1080/09273948.2023.2256850",

language = "English (US)",

journal = "Ocular Immunology and Inflammation",

issn = "0927-3948",

publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - Immunogenicity of Adalimumab in Patients with Non-Infectious- Uveitis

T2 - Systematic Review and Meta-Analysis

AU - Pachón-Suárez, Diana Isabel

AU - Zárate-Pinzón, Laura

AU - Cifuentes-González, Carlos

AU - Rojas-Carabali, William

AU - Mejía-Salgado, Germán

AU - Pineda, Juan Sebastián

AU - Peña-Pulgar, Luisa Fernanda

AU - de-la-Torre, Alejandra

PY - 2023/10/5

Y1 - 2023/10/5

N2 - Objective: To review the prevalence, incidence, and risk factors for developing anti-drug antibodies (AAA) in patients with non-infectious uveitis (NIU) treated with Adalimumab (ADA). Methods: A systematic literature search was performed on PubMed, EMBASE, Virtual Health Library, Cochrane, and medRxiv. Meta-analysis was performed using random effects. Results: Nine out of 2,373 studies were included. The prevalence of AAA in NIU patients treated with ADA was 9% (95% CI: 2% to 37%, I2 = 95% with a P<0.01), it was significantly higher in real-life scenarios (observational studies) than in clinical trials. The pooled incidence at 12 months was 27% (CI 95% 16%-42% I2 = 0%). Several factors have been associated with AAA generation in NIU patients, including the non-use of concomitant immunosuppressants, presence of autoimmune systemic disease, female gender, etc. Conclusion: This study showed that AAA prevalence is higher in real-life scenarios compared to clinical trials. Further research is needed to elucidate the factors that trigger AAA generation in NIU patients.

AB - Objective: To review the prevalence, incidence, and risk factors for developing anti-drug antibodies (AAA) in patients with non-infectious uveitis (NIU) treated with Adalimumab (ADA). Methods: A systematic literature search was performed on PubMed, EMBASE, Virtual Health Library, Cochrane, and medRxiv. Meta-analysis was performed using random effects. Results: Nine out of 2,373 studies were included. The prevalence of AAA in NIU patients treated with ADA was 9% (95% CI: 2% to 37%, I2 = 95% with a P<0.01), it was significantly higher in real-life scenarios (observational studies) than in clinical trials. The pooled incidence at 12 months was 27% (CI 95% 16%-42% I2 = 0%). Several factors have been associated with AAA generation in NIU patients, including the non-use of concomitant immunosuppressants, presence of autoimmune systemic disease, female gender, etc. Conclusion: This study showed that AAA prevalence is higher in real-life scenarios compared to clinical trials. Further research is needed to elucidate the factors that trigger AAA generation in NIU patients.

UR - https://www.scopus.com/pages/publications/85173429078

UR - https://www.scopus.com/pages/publications/85173429078#tab=citedBy

U2 - 10.1080/09273948.2023.2256850

DO - 10.1080/09273948.2023.2256850

M3 - Research Article

C2 - 37796609

AN - SCOPUS:85173429078

SN - 0927-3948

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

ER -

Immunogenicity of Adalimumab in Patients with Non-Infectious- Uveitis: Systematic Review and Meta-Analysis

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this